Johnson & Johnson (NYSE:JNJ – Get Rating) issued an update on its FY22 earnings guidance on Tuesday morning. The company provided EPS guidance of $10.15-10.35 for the period, compared to the Thomson Reuters consensus EPS estimate of $10.51. The company issued revenue guidance of $97.3-98.3 billion, compared to the consensus revenue estimate of $99.35 billion.Johnson & Johnson also updated its FY 2022 guidance to $10.150-$10.350 EPS.
JNJ stock opened at $177.66 on Tuesday. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.12 and a current ratio of 1.35. Johnson & Johnson has a one year low of $155.72 and a one year high of $184.20. The company’s 50 day moving average price is $172.50 and its two-hundred day moving average price is $168.01. The company has a market capitalization of $467.12 billion, a PE ratio of 22.75, a price-to-earnings-growth ratio of 2.71 and a beta of 0.72.
Johnson & Johnson (NYSE:JNJ – Get Rating) last released its quarterly earnings results on Tuesday, April 19th. The company reported $2.67 earnings per share for the quarter, beating the consensus estimate of $2.61 by $0.06. The business had revenue of $23.43 billion for the quarter, compared to analysts’ expectations of $23.62 billion. Johnson & Johnson had a net margin of 22.26% and a return on equity of 37.46%. The firm’s revenue for the quarter was up 5.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.59 earnings per share. On average, research analysts predict that Johnson & Johnson will post 10.48 EPS for the current year.
A number of research analysts have recently commented on the company. StockNews.com assumed coverage on Johnson & Johnson in a research report on Thursday, March 31st. They set a strong-buy rating for the company. The Goldman Sachs Group raised their price target on Johnson & Johnson from $163.00 to $181.00 and gave the stock a neutral rating in a report on Tuesday, April 12th. Raymond James raised their price objective on Johnson & Johnson from $185.00 to $195.00 and gave the stock an outperform rating in a research note on Thursday, April 14th. Sanford C. Bernstein cut Johnson & Johnson from an outperform rating to a market perform rating and boosted their price objective for the company from $180.00 to $183.00 in a research report on Wednesday, March 16th. Finally, Morgan Stanley lowered their price objective on Johnson & Johnson from $175.00 to $173.00 and set an equal weight rating on the stock in a research note on Wednesday, April 6th. Four equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Johnson & Johnson has an average rating of Buy and an average target price of $184.57.
In related news, VP Thibaut Mongon sold 23,681 shares of the firm’s stock in a transaction that occurred on Thursday, March 17th. The stock was sold at an average price of $176.25, for a total value of $4,173,776.25. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 0.35% of the company’s stock.
A number of institutional investors have recently added to or reduced their stakes in the business. Flagship Harbor Advisors LLC increased its position in Johnson & Johnson by 1.0% during the fourth quarter. Flagship Harbor Advisors LLC now owns 31,370 shares of the company’s stock worth $5,366,000 after buying an additional 311 shares in the last quarter. Monolith Advisors purchased a new position in Johnson & Johnson during the fourth quarter worth $69,000. Center for Financial Planning Inc. increased its position in Johnson & Johnson by 12.0% during the third quarter. Center for Financial Planning Inc. now owns 13,573 shares of the company’s stock worth $2,192,000 after buying an additional 1,459 shares in the last quarter. OLD Mission Capital LLC purchased a new position in Johnson & Johnson during the third quarter worth $362,000. Finally, Lombard Odier Asset Management USA Corp purchased a new position in Johnson & Johnson during the fourth quarter worth $698,000. 67.84% of the stock is owned by institutional investors.
Johnson & Johnson Company Profile (Get Rating)
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- 3 No-Brainer Stocks to Buy with $1000
- Rite Aid Stock is Getting Cheap Enough to Buy Here
- Analysts Reel In Netflix Targets Ahead Of Q1 Earnings
- MarketBeat Podcast: Making Money in the Red-Hot Housing Market
- Banking On Bank Of America
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.